The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.075
Bid: 2.95
Ask: 3.20
Change: 0.245 (8.52%)
Spread: 0.25 (8.475%)
Open: 2.875
High: 3.12
Low: 2.875
Prev. Close: 2.875
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK DIRECTOR DEALINGS SUMMARY: Landsec CEO Buys GBP300,000 Worth

Fri, 20th Nov 2020 14:51

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Friday and not separately reported by Alliance News:

----------

Land Securities Group PLC - London-based commercial property developer - Chief Executive Officer Mark Allan buys 45,695 shares at GBP6.82, worth GBP311,772, on Thursday. Landsec last week reported a wider interim loss and a fall in net asset value but reinstated its dividend.

----------

SSE PLC - electricity utility based in Perth, Scotland - Colin Nicol, outgoing managing director of electricity distribution business, SSEN Distribution, sells 18,212 shares at GBP14.11, worth GBP256,990, on Wednesday.

----------

RSA Insurance Group PLC - London-based general insurance - Chief Legal Officer Charlotte Heiss sells 29,968 shares at GBP6.75, worth GBP202,344, on Thursday. RSA on Wednesday said it has reached an agreement to be sold and split up in a deal with a two-headed consortium which values the former Royal & Sun Alliance Insurance Group at GBP7.2 billion.

----------

Spirent Communications PLC - Crawley, England-based provider of testing, analytics and security for telecommunications networks - Dean Ritchie, associate of Chief Financial Officer Paula Bell, buys 50,000 shares at GBP2.57, worth GBP128,740, on Thursday. Bell now interested in 363,884 shares.

----------

Jardine Matheson Holdings Ltd - Hong Kong-headquartered holding company with interests in retail, property, hotels and motor dealerships - Ruby Weatherall, associate of Director Percy Weatherall, sells 3,100 shares at USD51.35, worth USD159,193, in Singapore on Thursday.

----------

H&T Group PLC - Surrey, England-based pawnbroker - CFO Richard Withers buys 10,000 shares for 227.4 pence, worth GBP22,740, on Wednesday.

----------

Allergy Therapeutics PLC - Sussex-based biotechnology firm focused on allergy vaccines - Non-Executive Chair Peter Jensen buys 100,000 shares at 14p, worth GBP14,000, on Thursday.

----------

easyJet PLC - Luton Airport-based budget airline - Non-Executive Director Nicholas Leeder buys 1,346 shares mostly at GBP7.53, worth GBP10,140, on Thursday.

----------

Henderson High Income Trust PLC - investment trust aiming for high-income stream and prospects of capital growth - Director Jeremy Rigg buys 10,000 shares at GBP1.46, worth GBP14,605, on Friday.

----------

Dunedin Enterprise Investment Trust PLC - invests in UK mid-market companies - Directors sell shares as part of company's tender offer at GBP3.85 on November 12. Brian and Fionnlagh Finlayson sell 27,572 shares. Duncan, Rosemary and Victoria Budge sell 12,449 shares. Angela and David Lane sell 4,307. Company bought back 2.5 million shares in total, spending about GBP9.8 million.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
23 Oct 2018 16:11

BlackRock Lowers Allergy Therapeutics Stake Below Threshold (ALLISS)

LONDON (Alliance News) - Allergy Therapeutics PLC said Tuesday that BlackRock Inc lowered its stake in the company to below the 5% threshold.Prior to the deal, BlackRock held a 5.1% in the

Read more
26 Sep 2018 12:42

Allergy Therapeutics Interim Loss Widens But Germany Pushes Revenue Up

LONDON (Alliance News) - Allergy Therapeutics PLC on Wednesday said its loss widened in the first half of 2018, but revenue rose on strong performance in Germany and a strengthening of the company

Read more
19 Jul 2018 11:08

Allergy Therapeutics To Raise GBP11 Million Via Share Issue (ALLISS)

LONDON (Alliance News) - Allergy Therapeutics PLC said Thursday that it will raise up to GBP10.6 million via placing and subscription.The pharmaceutical company focused on allergy vaccines

Read more
29 May 2018 11:19

Allergy Therapeutics Reveals Good Results From Dust Mite Allergy Tests

LONDON (Alliance News) - Biotechnology firm Allergy Therapeutics PLC said it will present positive new data on its dust mite allergy treatment at a congress in Germany on Tuesday.Allergy is

Read more
21 May 2018 11:49

Allergy Therapeutics Reports Positive Results From Grass Pollen Study

LONDON (Alliance News) - Allergy Therapeutics PLC said Monday it saw positive results from its grass pollen allergy treatment phase II dose ranging study as it prepares to commence in phase III it

Read more
14 May 2018 12:24

Allergy Therapeutics Gets Positive Indications In Latest MCT Study

LONDON (Alliance News) - Biotechnology firm Allergy Therapeutics PLC on Monday said it has received positive new data in a study investigating its microcrystalline tyrosine-based results, it said,

Read more
16 Mar 2018 17:30

DIRECTOR DEALINGS: Allergy Therapeutics Non-Executive Lifts Stake

LONDON (Alliance News) - Pharmaceutical company Allergy Therapeutics PLC said Friday Non-Executive Director Tunde Otulana acquired shares on Thursday.Otulana acquired a

Read more
7 Mar 2018 13:42

Allergy Therapeutics Profit Falls On Costs As Pivotal Year Looms

LONDON (Alliance News) - Allergy Therapeutics PLC said Wednesday half year profit fell due to higher research and development costs, as the company prepares for 2018 clinical

Read more
14 Feb 2017 14:46

Allergy Therapeutics gets trial go-ahead in Spain

(ShareCast News) - Specialty pharmaceutical company Allergy Therapeutics announced on Tuesday that its Phase I clinical study investigating the safety and tolerability of Acarovac MPL received 'Clinical Trial Application' approval in Spain. The AIM-traded firm said it now expected the formulation to

Read more
14 Feb 2017 08:49

Allergy Therapeutics' House-Dust Mite Allergy Vaccine Trial Approved

Read more
2 Nov 2016 09:41

New broad patent strengthens Allergy Therapeutics portfolio

(ShareCast News) - Vaccine-focused pharmaceutical company Allergy Therapeutics announced on Wednesday that the European Patent Office has granted a broad technology patent relating to the its unique microcrystalline tyrosine depot adjuvant manufacturing process. The AIM-traded firm said the patent c

Read more
2 Nov 2016 09:29

Allergy Therapeutics Granted EU Patent For Microcrystalline Tyrosine

Read more
10 Oct 2016 11:59

Allergy Therapeutics examines potential of adjuvant portfolio

(ShareCast News) - Allergy Therapeutics will look into potential wider applications for its adjuvant technology after recent clinical research produced encouraging indications about both allergy vaccination and infectious disease applications. Microcrystalline tyrosine (MCT), an aluminium-free depot

Read more
29 Sep 2016 11:55

DIRECTOR DEALINGS: Allergy Therapeutics Chairman Lifts Stake

Read more
28 Sep 2016 10:41

DIRECTOR DEALINGS: Allergy Therapeutics Finance Boss Buys First Shares

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.